IN THE CLAIMS

1 (Currently Amended). Substantially homogeneous glycosylated human tumor necrosis factor-alpha (TNF-α) having cytotoxic biological activity~~.~~, with the proviso that said TNF-α is not labeled with a detectable group.

2 (Currently Amended). A method for preparing substantially homogeneous glycosylated human tumor necrosis factor-alpha (TNF-α) exhibiting cytotoxic biological activity, comprising:

D1 (a) ligating DNA encoding human TNF-α, or a mutant thereof exhibiting cytotoxic biological activity, which mutant has its cytotoxic biological activity neutralized by antisera raised against human glycosylated TNF-α, to a replicable expression vehicle to obtain a replicable recombinant DNA comprising said DNA and said replicable expression vehicle;

(b) transforming eukaryotic cells with said replicable recombinant DNA to form transformants;

(c) culturing said transformants to cause said transformants to express said glycosylated human TNF-α; and

(d) isolating said glycosylated human TNF-α from the cultured transformants~~.~~,

with the proviso that the said glycosylated TNF-α isolated from the cultured transformants is not labeled with a detectable group.

3 (Previously Amended). The method according to claim 2, further comprising the step of purifying the isolated glycosylated human TNF-α.

4 (Original) A method in accordance with claim 2, wherein said eukaryotic cells are Chinese hamster ovary cells.

5 (Previously Amended). A composition consisting essentially of glycosylated human tumor necrosis factor-alpha (TNF-α) having cytotoxic biological activity and at least one pharmaceutically acceptable carrier, diluent, or excipient.

D1

6 (Previously Amended). In the method for treating a human disease or condition treatable by the administration of an effective amount of human tumor necrosis factor-alpha (TNF-α) alone or in combination with other active principles or inactive carriers, diluents or excipients, the improvement wherein said human TNF-α is glycosylated human TNF-α exhibiting cytotoxic biological activity.

7 (Currently Amended). A method in accordance with claim 2, wherein, in said ligating step, said DNA ~~encoding human TNF-α or a mutant thereof~~ encodes human TNF-α.

8 (Previously Amended). The method according to claim 7, further comprising the step of purifying the isolated glycosylated human TNF-α.

9 (Original). A method in accordance with claim 7, wherein said eukaryotic cells are Chinese hamster ovary cells.

10 (Previously Amended). A composition consisting essentially of a purified glycosylated human TNF-α produced by the process of claim 3, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

11 (Previously Amended). In the method for treating a human disease or condition treatable by the administration of an effective amount of human TNF-α alone or in combination with other active principles or inactive carriers, diluents or excipients, the improvement wherein said human TNF-α is a purified glycosylated human TNF-α produced by the process of claim 3.

D1

12 (Previously Amended). Substantially homogeneous glycosylated TNF-α having cytotoxic biological activity, produced by the process of claim 2.